Stock Scorecard
Stock Summary for Centessa Pharmaceuticals plc (CNTA) - $22.52 as of 1/15/2026 6:55:14 PM EST
Total Score
4 out of 30
Safety Score
28 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for CNTA
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for CNTA
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for CNTA
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for CNTA
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for CNTA (28 out of 100)
| Stock Price Rating (Max of 10) | 7 |
| Historical Stock Price Rating (Max of 10) | 3 |
| Stock Price Trend (Max of 10) | 10 |
| Book Value (Max of 10) | 3 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 4 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 6 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | -10 |
Latest News for for CNTA
Financial Details for CNTA
Company Overview |
|
|---|---|
| Ticker | CNTA |
| Company Name | Centessa Pharmaceuticals plc |
| Country | N/A |
| Description | Centessa Pharmaceuticals PLC, headquartered in Cambridge, UK, is a pioneering biotechnology firm that employs a distinctive drug discovery and development platform aimed at revolutionizing treatment options. The company has cultivated a robust pipeline that addresses significant unmet needs in oncology and rare diseases, emphasizing its dedication to advancing innovative therapies. By integrating cutting-edge scientific research with in-depth market insights, Centessa is strategically positioned to become a formidable entity in the biopharmaceutical industry, committed to providing transformative solutions for patients worldwide. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 9/30/2025 |
| Next Earnings Date | 3/26/2026 |
Stock Price History |
|
| Last Day Price | 22.52 |
| Price 4 Years Ago | 3.10 |
| Last Day Price Updated | 1/15/2026 6:55:14 PM EST |
| Last Day Volume | 679,075 |
| Average Daily Volume | 1,300,357 |
| 52-Week High | 30.58 |
| 52-Week Low | 9.60 |
| Last Price to 52 Week Low | 134.58% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 58.69 |
| Sector PE | 54.65 |
| 5-Year Average PE | -9.20 |
| Free Cash Flow Ratio | 64.34 |
| Industry Free Cash Flow Ratio | 12.67 |
| Sector Free Cash Flow Ratio | 28.78 |
| Current Ratio Most Recent Quarter | 10.57 |
| Total Cash Per Share | 0.35 |
| Book Value Per Share Most Recent Quarter | 2.24 |
| Price to Book Ratio | 10.89 |
| Industry Price to Book Ratio | 10.48 |
| Sector Price to Book Ratio | 43.34 |
| Price to Sales Ratio Twelve Trailing Months | 216.39 |
| Industry Price to Sales Ratio Twelve Trailing Months | 35.65 |
| Sector Price to Sales Ratio Twelve Trailing Months | 19.82 |
| Analyst Buy Ratings | 11 |
| Analyst Strong Buy Ratings | 3 |
Share Statistics |
|
| Total Shares Outstanding | 146,076,000 |
| Market Capitalization | 3,289,631,520 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | -56.04% |
| Reported EPS 12 Trailing Months | -1.89 |
| Reported EPS Past Year | -0.99 |
| Reported EPS Prior Year | -1.99 |
| Net Income Twelve Trailing Months | -242,698,000 |
| Net Income Past Year | -235,757,000 |
| Net Income Prior Year | -151,085,000 |
| Quarterly Revenue Growth YOY | 0.00% |
| 5-Year Revenue Growth | 0.00% |
| Operating Margin Twelve Trailing Months | -1,425.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 50,811,000 |
| Total Cash Past Year | 383,221,000 |
| Total Cash Prior Year | 128,030,000 |
| Net Cash Position Most Recent Quarter | -59,005,000 |
| Net Cash Position Past Year | 274,281,000 |
| Long Term Debt Past Year | 108,940,000 |
| Long Term Debt Prior Year | 75,700,000 |
| Total Debt Most Recent Quarter | 109,816,000 |
| Equity to Debt Ratio Past Year | 0.79 |
| Equity to Debt Ratio Most Recent Quarter | 0.73 |
| Total Stockholder Equity Past Year | 401,545,000 |
| Total Stockholder Equity Prior Year | 236,244,000 |
| Total Stockholder Equity Most Recent Quarter | 301,574,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -181,170,005 |
| Free Cash Flow Per Share Twelve Trailing Months | -1.24 |
| Free Cash Flow Past Year | -142,089,000 |
| Free Cash Flow Prior Year | -160,511,000 |
Options |
|
| Put/Call Ratio | 0.89 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -1.12 |
| MACD Signal | -0.99 |
| 20-Day Bollinger Lower Band | 18.02 |
| 20-Day Bollinger Middle Band | 24.14 |
| 20-Day Bollinger Upper Band | 30.26 |
| Beta | 1.57 |
| RSI | 32.47 |
| 50-Day SMA | 18.44 |
| 150-Day SMA | 0.00 |
| 200-Day SMA | 0.00 |
System |
|
| Modified | 1/16/2026 8:23:49 PM EST |